Last Seen Blogs
fruitloop509
Fruitloop509
janghyungf
Bri
rodsredram
muscles1964
11511
the moon
writerevent9
The Life of Fisker 129
Text
Body Contouring Market In-Depth Analysis Globally by Top Key Players
According to the reports on the global Body Contouring Market, Market Research Future (MRFR) claims that the market is expecting a CAGR of 9.8 % during the forecast period (2017-2023). Body contouring is the process of altering a body part to give it a definitive shape and improving the appearance. The process often includes removal or transfer of fat. Thigh, abdomen, and buttocks often go under the knife to get this sort of fat removed.
The global body contouring market is expecting a good prospect in the coming years as the improved safety and efficacy of these procedures are ensuring more takers for the market. At the same time, media and entertainment in many cases are playing an important role in pushing this notion forward of maintaining a distinct shape. Rising health-awareness is also promoting such notions. At the same time, technology is also having a significant impact on the global market. Products have now become easy-to-use, cost-effective, and less painful owing to which a greater number of people are now opting for such options.
Segmentation:
The global body contouring market, as per the report of MRFR, is segmented by type of body contouring devices ,into invasive devices, minimally invasive devices & non-invasive devices. Non-invasive devices and minimally invasive devices are segments that enjoy major tractions in the market owing to the preference of patients. Companies are also investing significantly in developing state-of-the-art technologies to focus on features such as enhanced safety and cost-effectiveness.
Based on the invasive devices, the body contouring market can be segmented into ultrasound assisted liposuction and others.
Based on the non-Invasive devices, the body contouring market encompasses radio frequency lipoplasty devices, and high intensity focused ultrasound lipoplasty devices.
Based on the minimally invasive devices, the body contouring market is segmented into laser-assisted lipolysis devices, and radio frequency assisted liposuction devices.
Regional Analysis:
MRFR, in a region-specific analysis of the global body contouring market, includes namely, North America, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). This type of segmentation would allow easy analysis of growth pockets.
North America is currently in-charge of the global body contouring market. The regional growth is getting spurred by huge demand from the obese population. It is also benefiting from the presence of several market titans who have engaged themselves in an intense competition to develop new products. This is keeping the market alive. Europe’s market, feature-wise, is also on the same plain. Availability of better treatments and a substantial population suffering from diabetes are expected to take the regional market forward.
The APAC market is expected to rise with a substantial CAGR during the forecast period. India and China are going to contribute substantially owing to a large number of the population where the obese population is always on the rise. Increase in per capita income is also helping people in opting for such treatments which are providing the market with a much-needed thrust.
Competitive Landscape:
The global body contouring market is getting impacted by several companies who are actively participating in deciding the market growth for the coming years. MRFR profiled them for the report on the market and included the latest updates to ensure better market analysis. These companies are Alma Lasers (Israel), Meridian (Michigan), Cynosure (US), Lumenis (Israel), Palomar Medical Technologies (US), GlobalMed Technologies (US),), Andrew Technologies (Canada), Valeant Canada Syneron Medical (Israel), Asclepion Laser Technologies (Germany), Cutera (US Invasix Aesthetic Solutions (US), Wells Johnson Company (US), InMode (US), Human Med (Germany), Fotona (Slovenia), Chromogenex (UK), BTL Industries (US), Erchonia (US), and others.
In April 2019, Candela Corporation launched its Vbeam Prima laser system in Canada. The object comprises a 1064 nm wavelength, advanced 595 nm pulsed dye laser, two dermal cooling options, and other pulsed dye applications. Candela has made a name by developing body contouring devices, and their latest product is expected to control the market quite easily.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Body Contouring Market#Body Contouring#Body Contouring Market Size#Body Contouring Market Share#Body Contouring Market Analysis
0 notes
Text
Anesthesia Delivery Devices Market Size, Regional Outlook, and Forecast to 2027
Anaesthesia delivery devices play a pivotal role during a medical surgery where it helps in making the patient unconscious during the procedure. The device generates, blends, and delivers fresh medical gas flow with anaesthetic agents to have control over the entire process. The process often includes a mechanical ventilator, breathing system, suction equipment, and patient monitoring devices to ensure smooth workflow. MRFR in their detailed report on the said market included segmental analysis and factors that can impact the market in the coming years. The report also contains expert comments and updated information on the major market players’ portfolios.
It has been found that the expected anesthesia delivery devices market value is expected to grow at a CAGR of 8.2% during the forecast period. The anaesthesia delivery devices market centers around the growing need for surgical procedure across the world as the prevalence of chronic diseases is on the rise. Advanced technologies are amply backing up the modern surgical requirements and, in the process, are fostering growth for the market. However, the supply-demand relationship is facing some crises globally. Both the developed and developing countries are facing a shortage regarding anaesthesia delivery devices. Manufacturers across the globe are trying to figure out some sort of solution. One such is the integration of artificial intelligence (AI) that can ensure specific delivery and reduce the cost in the process. Such technological association can surely guide the anaesthesia delivery devices market to better prospects.
Segmentation:
As described in the MRFR report, the global anaesthesia delivery devices market can be segmented by types and end-users.
Based on types, the anaesthesia delivery devices market can be segmented monitoring devices, anaesthesia delivery devices, disposables device and other. The disposables device segment includes anaesthesia masks, anaesthesia delivery system and anaesthesia accessories.
Based on the end-users, the anaesthesia delivery devices market comprises hospitals, clinics, research facilities, and others.
Regional Analysis:
Geographically, upon considering the inputs by MRFR on the anaesthesia delivery devices market, the report can be segmented by Asia Pacific (APAC), Europe, North America, and the Rest-of-the-World (RoW).
The APAC region is currently leading the global market, and the market demography is expected to remain the same. This can happen as the regional market is also expecting the fastest CAGR during the forecast period. Countries such as India and China, with their revamped healthcare sector and the huge population has tapped into a vast patient pool who require surgeries of different sorts. In the process, they have widened the scale in which the anaesthesia delivery devices market can operate.
North America can take credit for being the second largest market. Its substantial revenue can be attributed to the advanced technologies, easy accessibility to products & services, and the emphasis on providing the best equipment in the industry is fostering the growth in the region.
Europe has considerable control over the global market as many of the manufacturing companies are from the region. Countries such as the UK, Germany, and France, are boasting off their advanced technology, affordability power, and government initiatives in research and development sector can trigger good responses from the regional market in the coming years.
Competitive Landscape:
Notable market players operating in the global anaesthesia delivery devices market are MEDTRONIC (Republic of Ireland), Teleflex (US), MAQUET Holding B.V. & Co. KG. (Germany), Smiths Medical (UK), GE Healthcare (US), Sedana Medical (Sweden), Drägerwerk AG & Co. (Germany), OSI Systems (US), ResMed (US), Fisher, Paykel (New Zealand), Philips Healthcare (Netherland), Intersurgical Ltd (UK), Covidien plc (UK), Getinge Group (Sweden) and others.
In August 2018, Hologic came up with a fluid management system with an aim to help in hysteroscopic procedures. The setup has a modern touchscreen and almost noiseless functioning ability. Fluid capacity, deficit, and how much content left in the fluid bag would get displayed on the monitor that would ease the entire process.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Anesthesia Delivery Devices Market#Anesthesia Delivery Devices#Anesthesia Delivery Devices Market Growth#Anesthesia Delivery Devices Market Research#Anesthesia Delivery Devices Market News
0 notes
Text
Refurbished Medical Devices Market Application, Growth Factors, Development and Forecast 2027
Refurbished medical devices market size is estimated to grow by 11.7% with USD 20209.5 million by 2027. Hospital budget cuts, a large inventory of used or old medical devices, rising demand for capital-intensive diagnostic imaging equipment, e-commerce platform easing the purchase of refurbished medical equipment, growing preference for eco-friendly products, and an increasing number of diagnosis are all contributing to the global refurbished medical equipment market's growth. The market's expansion was also aided by an increase in the patient population. The expansion of this industry has been fueled by the rising prevalence of cancer and other disorders. Furthermore, rising privatization, the presence of many low and medium budget hospitals and clinics, and rising demand for refurbished medical devices due to their low cost all contribute to the market's growth.
Cost containment pressures on healthcare organizations, a big inventory of old or used medical devices, the rising trend of medical tourism, and increased investments by private healthcare institutions are some of the reasons driving market expansion. With the advancement of technology, there has been a growing trend of "cheap buying," which is the driving force behind the growth of the refurbished device market. In addition to new medical equipment, there is a growing market for refurbished medical equipment all around the world. In reality, a growing number of new hospitals are choosing alternative choices to reduce construction expenditures. Several hospitals prefer refurbished medical equipment since they demand less capital investment, allowing healthcare providers to provide healthcare services at lower rates to patients. As a result, the market is likely to grow throughout the forecast period.
Furthermore, demand for reconditioned medical devices is substantially higher in low- and middle-income nations, with poor health infrastructure and limited access to healthcare resources being two of the main factors. In such countries, refurbished smartphones are simply accessible, promoting market growth. As a result, the market for refurbished medical gadgets is booming. The need for refurbished medical devices, such as mechanical ventilators, is predicted to skyrocket as a result of the COVID-19 epidemic. The healthcare industry, on the other hand, is still dealing with a significant supply chain disruption that has had a severe impact on refurbished medical devices.
Large import duties and a lack of understanding about refurbished medical gadgets may stifle the market's growth.
Market Segmentation
Global refurbished medical devices market is segmented on the basis of diagnostic devices into X-Ray Machines, CT scanners, Ultrasound Systems, MRI machines, ECG systems, patient monitors and other.
On the basis of therapeutic devices the market is segmented in heart-lung machines, coagulation analyzers, infant incubators and warmers, defibrillators, infusion pumps and other.
Regional Overview
On regional basis, global refurbished medical devices Industry is dominated by North America.
The greatest market for refurbished medical devices is in North America. The rise of the refurbished medical equipment market in North America is due to a large patient population, an ageing population, and cost reduction challenges connected to healthcare budgets. The market in North America has been driven by rising awareness of refurbished equipment and a well-developed healthcare sector.
Europe and Asia Pacific have a market that is essentially same. Europe is the second-largest market, with rising awareness of reconditioned medical devices and weak reimbursement rules for new medical devices driving growth. People have been driven to accept refurbished medical gadgets due to economic issues and low product costs.
However, the market for refurbished medical devices in Asia Pacific is growing at the fastest rate. The high cost of new medical gadgets, along with the presence of a large number of low-cost hospitals, has resulted in an expansion in this market in Asia Pacific. In the face of the pandemic, the acceptance and use of refurbished medical gadgets, such as patient monitoring devices, is projected to rise in the region's growing countries. Furthermore, the growing number of hospitals and diagnostic centers, as well as the governments and private organizations’ increased focus on rural development, resulted in a high demand for reconditioned medical devices in this region.
Competitive Dynamics
GE Healthcare (US), Stryker Corporation (US), Phillips Healthcare (Netherlands), Siemens Healthcare (Germany), Agito Medical (Denmark), DMS Topline (U.S.), Johnson & Johnson (US), First Source, Inc (U.S.), and Soma Technology (U.S.), Toshiba Medical System (Japan), Block Imaging International (US).
The presence of well-known enterprises in this region is projected to help the industry grow even further. The market has become more competitive as a result of the presence of numerous small and medium-sized businesses. Many of the main players are based in the United States. Increased alliances and collaboration among the market's main players will help to reduce competition.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Refurbished Medical Devices Market#Refurbished Medical Devices#Refurbished Medical Devices Market Analysis#Refurbished Medical Devices Market Trends
0 notes
Text
Contraceptive Drugs Market Size, Outlook, Analysis Report, Regional Outlook With Forecast 2027
Contraceptive drugs Market is expected to register 6.8% CAGR during the forecast period, , with a market value of USD 16790.02 Million. Whereas in progestin-only contraceptives (POP) mainly just change the viscosity of mucus and thin the endometrium. The factors which drive the market of contraceptives drugs are increasing need of population controls and increasing prevalence of sexually transmitted diseases. According to report published by World Health Organization (WHO) in 2016, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Additionally, report suggest that more than 500 million people are estimated to have genital infection with herpes simplex virus (HSV). Contraceptive drugs Market Growth is significant during forecast period.
Contraceptives drugs refers to the medicines that are used to prevent unwanted pregnancy. Contraceptives drugs consists one or more synthetic female sex hormones, if they contain both estrogen and progestin are known as combined oral contraceptive pills (COC) and if they contain only progestin are known as progestin-only contraceptives (POP). Both of them have different pattern to prevent pregnancy, combined oral contraceptives (COC) which includes both estrogen and progestin, restrain the normal process of releasing egg from an ovary (ovulation) and by altering the lining of the uterus in result it is unable to support a fertilized egg.
Global Contraceptive Drugs Market – Overview
The global contraceptive drugs market is showing the moderate growth; mainly due to increase to avoid unwanted pregnancies and their complication. Moreover, increasing incidence of STIs and the rapid increase in population. Most of the countries around the world are facing the issues of unintended pregnancy by adolescents, especially in developing region. According to report published by World Health Organization (WHO) in 2018, around 21 million girls aged 15 to 19 years and 2 million girls aged under 15 years become pregnant every years in developing regions. Moreover, around 16 million girls of aged 15 to 19 years and 2.5 million girls of aged 16 years give birth each year in developing regions.
Companies are showing much interest toward the contraceptive drugs market, as they feel there are huge opportunities and gaps between the market demand and supply of effective drugs. Thus, companies are investing more into research and development activities to introduce better drugs in the market. The development has been made by Pfizer in September 2015, when they announced that Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection, after getting the approval from UK Medicines and Healthcare Products Regulatory Agency (MHRA).
Many companies such as, Merck & Co., Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Bayer AG, Allergan plc, Janssen Global Services llc., Mankind Pharma Ltd. , Piramal Enterprises Ltd, and Reckitt Benckiser Plc are working to introduce best drugs in the market. All these development help market to get quality drugs and fulfill unmet requirement.
Market Key Players:
Merck & Co., Inc (U.S.), Pfizer Inc (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Allergan plc. (Ireland), Janssen Global Services llc. (U.S.), Mankind Pharma Ltd. (India), Piramal Enterprises Ltd (India), Reckitt Benckiser Plc (U.K), Church & Dwight (U.S.), The Female Health Company (U.S.), Mayer Laboratories (U.S.), Cooper Surgical (U.S.) are some of the leading players at the cutting edge of the competition in the market of Contraceptive drugs, globally.
Global Contraceptive drugs Market - Regional Analysis
The market of contraceptive drugs is much higher in the Americas region owing to increasing awareness among the people and high incidence rates of abortion. According to the report published by Centers for Disease Control and Prevention in 2015, around 229,715 babies were born from women aged between 15 to 19 years.
Europe is also considering the huge market for contraceptive drugs players, owing to the increasing government support and awareness about healthcare industries, and well developed technology. Moreover, companies from these region are more into export to the developing region which increase the market share around the globe.
Asia Pacific and the Middle East and Africa region are considering the big market. Whereas country like India and china of Asia Pacific region are considering fastest growing region due to the high rate of incidence of teen pregnancy. According to WHO, adolescent birth rates is 45 births per 1000 women in South-Eastern Asia and 7 births per 1000 women in Eastern Asia. Additionally they are open to adopt new treatment option from a developed country, this gap between the developed and developing countries will present significant growth opportunities for the contraceptive drugs market players in the coming years.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Contraceptive Drugs Market#Contraceptive Drugs#Contraceptive Drugs Market Research#Contraceptive Drugs Market Analysis#Contraceptive Drugs Market Trends
0 notes
Text
Antibody Drug Conjugate Market Dynamic Outlook and Influencing Key Growth
Antibody drug conjugate market growth is expected to grow by 19% by 2023. The antibody drug conjugate is a crucial biopharmaceutical therapy for cancer treatment. Antibody drug conjugates are the targeted therapy for the treatment of people suffering with cancer. It is the important class of highly potent biopharmaceutical drugs, with intend to target and kill only cancer cells. Antibody drug conjugates have quality of sensitive discrimination between healthy and diseased tissue.
Global Antibody drug conjugate Market- Competitive Analysis
Seattle Genetics (U.S.), ImmunoGen, Inc.(U.S.), Roche Holding AG (Switzerland), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Antikor (U.K), Vaccinex Inc (U.S.) are some of the leading players at the cutting edge of the competition in the market of antibody drug conjugate, globally.
Antibody drug conjugates represent an innovative therapeutic application that combines the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic. According to National Instituted of Health (NIH) it has been found that in 2016, a projected 1,685,210 new cases of cancer will be detected in the United States and 595,690 individuals will die from the disease which further increases the growth of the market. market report offers comprehensive study of the antibody drug conjugate manufacturing ,Overview, Regional Overview, Segments.
Global Antibody drug conjugate Market – Overview
The global antibody drug conjugate market is rising with a swift phase; mainly owing to increase in patient population suffering with cancer. This therapy have ability to treat different type of cancer such as endometrial and breast cancer. According to WHO, in 2015, around 570,000 women died owing to breast cancer globally, which are approximately 15% of all cancer deaths among women. Breast cancer is most frequent cancer among the women, and impacting around 1.5 million women every years. Rising consumer awareness about treatment with antibody drug conjugate therapy and increasing population globally leads the antibody drug conjugate market.
Companies are continuously invent new products to capture the market globally. Thus major players invest more in merger, collaboration, and acquisition, in order to lead the global market. In this regards, Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products. Where ImmunoGen will be responsible for the developing of the three ADC programs prior to any potential opt-in by Jazz. These collaboration help to introduce new quality drugs for the treatment of the cancer.
In 2017, Vaccinex Inc and Catalent Biologics to collaborate on antibody-drug conjugate development. In this collaboration company will combine the ActivMAb antibody with Catalent’s SMARTag conjugation technology, for generating unique and differentiated molecule to treat cancers. These collaboration also help in expanding the network around the globe. Which help companies to reach the patient population and capturing the market. Additionally, research and development will help company to leads the market. Increasing in cancer population globally is the factors that leads the market of antibody drug conjugate.
Global Antibody drug conjugate Market - Regional Analysis
The market of antibody drug conjugate is much higher in the Americas region, owing to high presence of population diagnosed with cancer and also have awareness of healthcare. Thus, market players have good opportunity to maximize their profit with in this region owing to high awareness of healthcare awareness. According to American Society of Clinical Oncology (ASCO) the 5-year survival rate for stage I NSCLC is about 47% which falls drastically to 10% for stage III. The 5-year survival rate for stage IV NSCLC is just around 1%.
Europe is also consider huge market for antibody drug conjugate players, owing to present of huge population affected with cancer. Government are more focusing on research and development to introduce new drugs for providing the best treatment to their citizen. According to Cancer research UK, in 2014, new cases of cancer are 356,860, including 579 cases of bone cancer.
Asia Pacific region is considering the huge market. Whereas country like India and china of are considering fastest growing region due to presence of huge population suffering with cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their public. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8 million deaths, and is the second leading cause of death across the globe.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Antibody Drug Conjugate Market#Antibody Drug Conjugate#Antibody Drug Conjugate Market Analysis#Antibody Drug Conjugate Market Size#Antibody Drug Conjugate Market Share
0 notes
Text
Blood Glucose Test Strip Market Growth, Trends, Types Analysis & forecast to 2027
The blood glucose test strip market is presumed to garner USD 18.5 billion during the forecast period (2015-2020). The market is presumed to register 6.2 % CAGR owing to the increasing diabetic population, asserts Market Research Future (MRFR). Blood glucose test strip can be referred to as a small non-reusable plastic strip. It is a crucial component of blood glucose meters that helps to monitor and control diabetes.
Drivers and Constraints Impacting the Market
Blood glucose test strips are self-testing strips which let pre-diabetic and diabetic people track their blood glucose level on a regular basis without visiting a diagnostic laboratory or a clinic. With the growing diabetic population, the global market for blood glucose test strip is considered to foster during the assessment period. For instance, as per the International Diabetic Federation, around 415 million people had diabetes in 2015. The number is estimated to reach 642 million by the end of 2040. Moreover, technological advancements such as accuracy of the tests along with awareness among the people regarding diabetes are stimulating the market growth.
On the flip side, product recall owing to the inefficiency of devices such as intense competition resulting in pricing pressure and false glucose reading are some of the major factors considered to impede the global blood glucose test strip market in the coming years.
Global Blood Glucose Test Strip Market: Segmental Analysis
The blood glucose test strip market has been segmented on the basis of technology, distribution channel, and region.
By mode of technology, the global blood glucose test strip market has been segmented into optical, thin film electrochemical, self Monitoring blood glucose test strips and thick film electrochemical.
By mode of distribution channel, the global blood glucose test strip market has been segmented into retail pharmacy and hospital pharmacy. Among these, the hospital pharmacy is likely to dominate the global market and is anticipated to maintain its dominance over the assessment period. The growth is attributed to the increasing preference for self-care testing among the patients to monitor diabetes.
Regional Insights
Geographically, the global blood glucose test strip market span across regions namely, North America, Europe, Asia Pacific, and the Middle East and Africa.
Among all the regions, North America is presumed to lead the global blood glucose test strip market with $ 7.89 billion revenue. The growth is attributed to the extensive use of information technology coupled with high expenditure on healthcare. Moreover, the presence of major medical device manufacturers and high adoption of latest technologies are considered to stimulate the market during the review period.
Europe is estimated to hold the second position in the global market and is likely to maintain its dominance during the review period. High healthcare expenditure led by France and Germany is anticipated to drive the global market.
The Asia Pacific region is presumed to expand at a rapid pace owing to the presence of major regions such as India and China which are expected to lead the market due to unmet needs. This region is presumed to expand at 12.9 % CAGR owing to the growing number of diabetic population.
Industry Updates
January 2018: Ascensia Diabetes Care has recently announced the expansion of its strategic alliance with the Insulet Corporation which is a leader in tubeless insulin pump technology. The expansion follows the worldwide non-exclusive development agreement that Ascensia had announced in June 2017, to connect its CONTOUR NEXT ONE blood glucose monitoring system with Insulet's next-generation Omnipod System.
Competitive Dashboard
The major players operating the global market are Apex Biotechnology Corp, Shanghai MicroSense, ALL Medicus, Beijing Yicheng Electronics, Elektronika, Nipro Diagnostics, Bayer Diabetes Care, B. Braun, LifeScan, ACON Laboratories, Jiangsu Yuyue, HMD BioMedical Inc., TaiDoc, Betachek National Diagnostics, Roche Diagnostics, i-SENS, Universal Biosensors, Abbott, SANNUO, AgaMatrix Inc, and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Blood Glucose Test Strip Market#Blood Glucose Test Strip#Blood Glucose Test Strip Market Trends#Blood Glucose Test Strip Market News#Blood Glucose Test Strip Market Research
0 notes
Text
Overt Hepatic Encephalopathy Market Size, Growth, Report Study, Demand, Key Players
Overt Hepatic Encephalopathy Market is expected to register 11.2% CAGR during the forecast period of 2019 to 2025 and held a market value of USD 54.28 Million in 2018.Hepatic encephalopathy is a disorder that occurs by a buildup of toxins in the brain which cause advance liver disease. People affected with hepatic encephalopathy get changed in their behavior, mood, speech, sleep, or the way they move. On the base of severity, hepatic encephalopathy is divided into two broad categories that is covert hepatic encephalopathy and overt hepatic encephalopathy. Overt hepatic encephalopathy (OHE) is the condition which is associated with increasing rates of hospitalizations and mortality, and poor quality of life. 40% of patients with cirrhosis during their clinical care develop overt hepatic encephalopathy.
The factors that causes overt hepatic encephalopathy during advanced liver disease are infected, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. According to the U.S. National Library of Medicine, 30-50% of patient with cirrhosis have a chance to develop overt hepatic encephalopathy. Additionally, owing to overt hepatic encephalopathy, there is the negative impact on the health related quality of life of the patient.
Global Overt hepatic encephalopathy Market – Overview
The global overt hepatic encephalopathy market is showing the moderate growth; mainly due to increase in patient population suffering with cirrhosis disease. Moreover, increase in consumption of alcohol also increase the prevalence of cirrhosis around the globe. According to World Health Organization (WHO), Alcohol consumption causes 20% to 50% of cirrhosis disease, epilepsy, poisonings, road traffic accidents, violence and several types of cancer.
Companies are showing much interest toward the overt hepatic encephalopathy market, as they feel there are huge opportunities and gaps between the market demand and supply of effective hepatic encephalopathy treatment. Liver transplant is the major cure consider in the treatment of overt hepatic encephalopathy. Thus, there is the lot of scope for companies to introduce better drugs which help to cure the disease. However, XIFAXAN 550, the drug in the market for the treatment of overt hepatic encephalopathy but they have few limitation, which generate the demand for a cost effective treatment. According to World Health Organization, (WHO), in 2015, around 887 000 deaths occurs globally, mostly from complications from cirrhosis and hepatocellular carcinoma. Report also suggest that, in some people, the hepatitis B virus can also cause a chronic liver infection that can later develop into cirrhosis, which turm into liver cancer.
Many companies such as, Alfa Wassermann S.p.A, Cosmo Pharmaceuticals S.p.A, KannaLife Sciences Inc., Ocer Therapeutics, Inc., Rebiotix Inc., Spherium Biomed S.L., and Umecrine Cognition AB are working to introduce best treatment in the market. All these development help market to get quality treatment and fulfill unmet requirement.
Global Overt hepatic encephalopathy Market - Regional Analysis
The market of overt hepatic encephalopathy is much higher in the Americas region. There is huge population suffering with liver diseases. According to reports published by the Centers for Disease Control and Prevention (CDC) in 2016, around 3.9 million people are diagnosed with liver disease that is approx. 1.6% of adults in the United States. Additionally, report suggests that 38,170 deaths occur owing to liver disease. Increase in prevalence of overt hepatic encephalopathy with increasing demand for the better treatment has boosted the growth of the market.
Europe is also considered a huge market for overt hepatic encephalopathy players, owing to the increasing prevalence of overt hepatic encephalopathy, increasing government support, and well developed technology. Moreover, increase in the incidence of high overt hepatic encephalopathy owing to consumption of alcohol also fuelling the growth of the market.
Asia Pacific and the Middle East and Africa region are considering the big market. Whereas, countries like India and China of Asia Pacific region are considered to be the fastest growing region due to the presence of huge population suffering with overt hepatic encephalopathy, additionally they are open to adopt new treatment option from a developed country, this gap between the developed and developing countries present significant growth opportunities for the overt hepatic encephalopathy market players in the coming years. Whereas, the Middle East and Africa are the low growing market due to his incapability of investment.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Overt Hepatic Encephalopathy Market#Overt Hepatic Encephalopathy#Overt Hepatic Encephalopathy Market Growth#Overt Hepatic Encephalopathy Market Size#Overt Hepatic Encephalopathy Market Share
0 notes
Text
Biopharmaceutical Excipients Market Trends, Demand, Growth and Key players 2027
According to MRFR analysis, the global biopharmaceutical excipients market is expected to register a CAGR of~6.8% from 2021 to 2027and is expected to hold a value of ~USD 3,114.6 million by 2027.
The global biopharmaceutical excipients market is driven by several factors, such as increasing demand for oral formulations across the globe, rising demand for customized medicines, and an increasing geriatric population. Other factors such as increasing patients with chronic ailmentscoupled with growing life expectancy are driving the production of biopharmaceuticals. In addition, increasing stress, back pains, body aches, and headaches has augmented the demand for topical type formulation, accelerating the market growth.
The industry players focus on expanding their global footprint by strategic partnerships, investing in some company’s stock, acquisitions, and product launches. For instance, in February 2020,ReForm Biologics (US) partnered with MilliporeSigma (US) to commercialize excipients used in biotherapeutics. In August 2019, LBB Specialties (US) announced the strategic partnership with MEGGLE (Germany)to expand its excipient distribution channel across the US. In December 2018, Roquette (France) bought a majority stake in excipient producer Crest Cellose (India) that enabled the company to expand its product portfolio and presence in the Indian generic pharmaceutical market. Furthermore, the prominent players focus on new developments, employee satisfaction, the transformation of their research wings, and expanding their distribution network. These factors will augment the market growth and will increase theproduct demand in the forecast timeline.
Regional Analysis
North America is projected to dominate the biopharmaceutical excipients market due to the growing adoption of the latest drug manufacturing technologies, increasing chronic diseases, and expansion of production capabilities of the industry players across the region. In addition, highinvestments were made in the development of new excipient variants to advance the product portfolio. Furthermore, the key players are involved in collaborations, mergers, and R&D activities that propel market growth.
Europe embraces the second-largest position in the biopharmaceutical excipients market due to growing investments in the pharmaceutical sector and increasing production capacity across the region. In addition, the region experienced high demands for pharmaceutical products. Moreover, countries such asGermany, Italy, the UK, France, and Spain have invested huge amounts in the manufacturing of new vaccines.
Asia-Pacific is anticipated to be the fastest-growing regional market over the projected timeline due to the rising investment in pharmaceutical research and production facilities, increasing consumption of medicines, and supportive government alliances and subsidy schemes. In addition, the availability of highly skilled research employees and an economical workforce is creating opportunities for the industry players.
Furthermore, the market in the Rest of the World is gaining importance due to the rising number of investors, growing geriatric population in countries such as Chile and Argentina, and expansion of the pharmaceutical market across Latin America. However, the availability of counterfeit pharmaceutical goods is hampering the biopharmaceutical excipient market. The pharmaceutical companies aim atinvesting in the Middle East & Africaregion owing to its technologically advanced labs and other research infrastructures. Countries such as Saudi Arabia and the UAE are hiring employees throughout the globe to advance their pharmaceutical market.
Segmentation
The global biopharmaceutical excipients market is categorized into product and formulation. Based on the product category, the market has been segregated into solubilizers & surfactants/emulsifiers, polyols and carbohydrates, vaccine excipient and specialty excipients. The carbohydrates segment is expected to hold a considerable share of the market in 2021. Increasing R&D activities for the development of lipid and protein excipient-based corona vaccines is fueling the market demand. In addition, the high demand for carbohydrate-based medicines for the infant segment is propelling the biopharmaceutical excipient market.
Based on formulation, the global biopharmaceutical excipients market has been classified as oral, topical, and injectables. The oral segmentheld the major share in 2020 due to the easy intake procedure and availability of oral medicines throughout the hospitals and retail stores. Additionally, the demand for oral and topical formulations is accelerating due to the growing preference for on-the-go treatment and ambulatory treatment services coupled with increasing cases of trypanophobia.
Key Players
Some of the key players in the global biopharmaceutical excipients market are Merck KGaA (Germany), Colorcon (BPSI Holdings Inc) (US), BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical Manufacturing Corp. (US), Roquette Frères (France), Clariant (Switzerland), DFE Pharma (Germany), J. Rettenmaier & Söhne Gmbh + Co Kg (Germany), and Evonik Industries AG (Germany).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Biopharmaceutical Excipients Market#Biopharmaceutical Excipients#Biopharmaceutical Excipients Market Trends#Biopharmaceutical Excipients Industry#Biopharmaceutical Excipients Market News
0 notes
Text
Chemiluminescence Immunoassay (CLIA) Analyzers Market Trends, Growth And Regional Outlook 2027
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market is expected to register a CAGR of 6.4% during the forecast period, with a market value of USD 8,205.22 Million.
Chemiluminescence immunoassay (CLIA) analyzers have been growing at a rapid pace over the last few years. The global chemiluminescence immunoassay (CLIA) analyzers market is rapidly booming due to the increasing prevalence of chronic and acute diseases, technological advancements, and high specificity provided by chemiluminescence immunoassay (CLIA) analyzers. However, the scarcity of skilled labor/healthcare professionals and stringent regulatory policies are hampering the growth of the market. Likewise, entry of market players in developing economies is likely to pose an opportunity for global chemiluminescence immunoassay (CLIA) analyzers market.
Segment Analysis
The Global Chemiluminescence Immunoassay (CLIA) Analyzers Market is segmented into Type, Product, Application, and End User. By type, the market has been segmented into high throughput, medium-throughput, serological immunoassay test and low throughput. Based on the product, the market has been segmented into reagents, analyzers, and consumables. The reagents are further classified into luminophore markers and enzymatic markers. By product, the analyzers are classified into automated and semi-automated. Based on the application, the global chemiluminescence immunoassay (CLIA) analyzers market has been categorized as hepatitis and retroviruses, oncology & endocrinology, cardiac markers, infectious disease, bone and mineral disorders, auto-immune diseases, allergy, GI stool testing, drug discovery and development, and others. On the basis of end-user, the market has been segmented into hospitals & clinics, medical & diagnostic laboratories, pharmaceutical companies, and others.
Regional Analysis
The Global Chemiluminescence Immunoassay (CLIA) Analyzers Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the global chemiluminescence immunoassay (CLIA) analyzers market. This is owing to the increasing prevalence of chronic diseases and rising expenses in research and development by healthcare institutions and government bodies.
The European market holds the second-largest position in the global chemiluminescence immunoassay (CLIA) analyzers market. Factors attributing to the growth of the market include increasing access to advanced treatment facilities, rising government initiatives to promote research to find a cure for chronic diseases, and high healthcare expenditure.
Asia-Pacific is estimated to be the fastest-growing region owing to the huge patient pool of chronic diseases, government initiatives of healthcare reform, and the presence of economically developing countries such as India and China.
The chemiluminescence immunoassay (CLIA) analyzers market in the Middle East & Africa accounts for the least market share due to the adequate healthcare infrastructure support accounted for a relatively smaller market share in 2018.
Key Players
MRFR recognizes the following companies as the Key Players in the Global Chemiluminescence Immunoassay (CLIA) Analyzers Market— F. Hoffmann-La Roche Ltd (Switzerland), Mindray (China), Fujirebio (Japan), Autobio (China), Siemens AG Healthcare (Germany), Abbott Laboratories (US), Ortho Clinical Diagnostics (US), Tosoh Corporation (Japan), DiaSorin SpA (Italy), Beckman Coulter, Inc. (US), and Shenzhen New Industries Biomedical Engineering Co., Ltd. (China) among others.
Key Findings of the Study
The Global Chemiluminescence Immunoassay (CLIA) Analyzers Market was valued at USD 4,995.25 million in 2018, is estimated to grow at USD 8,205.22 million by 2026 at a CAGR of 6.4 % during the assessment period
America accounted for the largest share of the global market due to the presence of a large number of medical device companies such as Ortho Clinical Diagnostics, Beckman Coulter, Inc., (US) and others offering CLIA analyzers
Based on types, the high throughput segment accounted for the largest market share in 2018
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Chemiluminescence Immunoassay (CLIA) Analyzers Market#Chemiluminescence Immunoassay (CLIA) Analyzers#Chemiluminescence Immunoassay (CLIA) Analyzers Market Research#Chemiluminescence Immunoassay (CLIA) Analyzers Market news#Chemiluminescence Immunoassay (CLIA) Analyzers Market Analysis
0 notes
Text
Gene Panel Market Competitive landscape, future, growth till 2027
Gene panel is a test that analyzes multiple genes for cancer-associated mutations at the same time. Gene panels offer a middle ground between single-gene sequencing (like BRCA1), which is certainly involved in disease risk and sequencing every gene in the genome. Gene panels enable the simultaneous screening of several genes.
The gene panel market in the global market is expected to grow at a high CAGR of 12.16% by the end of the forecasted period to account for a higher market value of approximately USD 4,347.32 million during the forecasted period in the global market.
Panels are typically customized for specific screening purposes; thus, the genes and specific gene regions on such panels are unique to the screening goals. The increasing prevalence of cancer and the benefits of gene panels are expected to drive the growth of the global gene panel market. However, limitations in genetic panel testing and inaccuracy of the test are expected to hamper the growth of the market.
Segment Analysis
The Global Gene Panel Market has been segmented by product & service, Technique, Design, Application, and End User.
The market, based on product & service, has been bifurcated into test kits and testing services. Based on the technique, the global gene panel market has been bifurcated into the amplicon-based approach and hybridization-based approach. On the basis of design, the global gene panel market has been bifurcated into predesigned gene panels and customized gene panels. Based on the application, the global gene panel market has been classified as cancer risk assessment, diagnosis of congenital disorders and pharmacogenetics. The global gene panel market based on end-user has been divided into hospitals, diagnostic laboratories, and others.
Regional Analysis
The global gene panel market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to hold the largest share of the global gene panel market during the assessment period. The rising prevalence of cancer and the presence of well-established players are expected to support the dominance of the Americas during the forecast period. Europe established substantial growth in the market owing to the incidence rates for all cancers projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035. This rising case of cancer, along with improving the efficiency of gene panels, is expected to drive the growth of the market. Asia-Pacific is estimated to be the fastest-growing regional market due to the growing healthcare expenditure and the presence of a large patient pool. The gene panel market in the Middle East & Africa is expected to witness gradual growth due to the increasing healthcare expenditure, rising investments by major market players, and growing patient pool in this region. For instance, according to the International Trade Administration, health expenditure in the UAE was USD 17 billion in 2017 and is expected to reach USD 21.3 billion by 2021.
Key Players
MRFR recognizes the following companies as the Key Players in the Global Gene Panel Market— Agilent Technologies Inc. (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Illumina Inc. (US), BGI Genomics (China), Integrated DNA Technologies, Inc. (the US), GENEWIZ (US), Novogene Corporation (US), Personalis, Inc. (the US), GATC Biotech AG (Germany), ArcherDX, Inc. (the US), GeneDx (Switzerland), and CENTOGENE AG (Germany).
Key Findings of the Study
The Global Gene Panel Market was valued at USD 1,988.76 Million in 2018 and is expected to register a CAGR of 12.16% during the assessment period of 2019 to 2025
The Americas accounted for the largest share of the global market
Based on the product & service, the testing services segment is expected to register the highest CAGR of 12.29% during the forecast period
Based on the technique, the amplicon-based approach segment is expected to register the highest CAGR of 12.52% during the forecast period
Based on the design, the predesigned gene panels segment accounted for the largest market share of 6% in 2018
Based on application, the cancer risk assessment segment accounted for a larger market share of 67.8% in 2018
Based on the end-user, the hospital's segment is expected to register the highest CAGR of 12.68% during the forecast period
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Gene Panel Market#Gene Panel#Gene Panel Market Trends#Gene Panel Market News#Gene Panel Market Research
0 notes
Text
Chronic Inflammatory Demyelinating Polyneuropathy Market Trends, Growth And Regional Outlook 2030
Autoimmune diseases are on the rise, and chronic inflammatory demyelinating polyneuropathy (CIDP) is no exception. Although CIDP is a rare disease, it has been growing in prevalence. Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder wherein the body's immune system attacks the myelin causing various symptoms such as numbness, weakness, and a lack of certain reflexes. According to the latest research report, the chronic inflammatory demyelinating polyneuropathy market size is poised to increase at a compound annual growth rate of a CAGR of 7.50 percent during the forecast timeframe of 2020-2030 reaching USD 6,577.10 million by the end of the review period.
Autoimmune diseases have been witnessed to be increasing in prevalence. According to the American Autoimmune Related Diseases Association, nearly 50 Mn Americas were recorded to have been suffering from autoimmune diseases in 2017. The cause of chronic inflammatory demyelinating polyneuropathy has not yet been identified and can occur in any individual regardless of genetic makeup. This has directly resulted in an increase in research and development with regards to treatment. For the chronic inflammatory demyelinating polyneuropathy market, growth is expected to induced by the increasing R&D related to plasma-derived medicines. Most recently in 2017, this resulted in the FDA approval of a new immune globulin intravenous treatment of CIDP called Privigen. Moreover, the market is being supported by the increasing awareness regarding chronic inflammatory demyelinating polyneuropathy (CIDP). Increasing incidences of this diseases combined with government intervention to provide support to patients suffering from chronic inflammatory demyelinating polyneuropathy will drive market growth. Favorable reimbursement policies and involvements of non-profit organizations are among the various factors driving the market's growth.
The market faces a few challenges with regards to the high cost of intravenous immunoglobin (IVIG) treatment as well as the various side effects associated with IVIG treatment. Common side effects include migraines, mild fever, myalgia, and several others. However, due to the consistent R&D activities taking place, the market is likely to witness opportunities in the form of advancements in CIDP treatments. The growing prevalence of the disease has created a strong demand for effective medication and treatment options which display high opportunity potential for market players.
Market Segmentation
The market structure which has been determined by various components in MRFR's report has been segmented on the basis of treatment & diagnosis, route of administration, end-user, and region. Treatment and cidp diagnosis have been segmented into treatment and diagnosis. The treatment segment which holds the most significant share of the market is sub-segmented into corticosteroids, intravenous immunoglobin (IVIG), plasmapheresis (plasma exchange), physiotherapy, and others. The treatment segment is also growing at the highest CAGR of 6.32% during the review period due to rising demand for effective treatments for CIDP. Among the various sub-segments, the IVIG sub-segment has achieved a leadership status due to the preference for IVIG as the first line of treatment for CIDP.
Route of administration of chronic inflammatory demyelinating polyneuropathy medication has been segmented into oral, intravenous, and others. Due to the high preference for IVIG treatment which enters the bloodstream directly to react faster, the intravenous segment by route of administration has both acquired the largest share of the market and is growing at the highest CAGR during the forecast period. The intravenous segment accounts for 85% of the total market share, followed by oral and others.
End-users in the chronic inflammatory demyelinating polyneuropathy market have been segmented into specialty neurological clinics, hospitals, research & academic laboratories, and others. Hospitals have amassed a 49% share of the global market due to their widespread presence and the preference for hospitals among patients. However, patients are increasingly seeing the value in specialty clinics where they may understand their illness better. As a result, the specialty neurological clinics segment is growing at the most rapid CAGR of 6.49% during the review period.
Key Players
MRFR's study of the global chronic inflammatory demyelinating polyneuropathy includes identification and analysis of the various market participants competing in the global market. Prominent competitors include Kedrion S.p.A, Octapharma, CSL Behring, Pfizer, Inc, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Baxter, Bio Products Laboratory Ltd., Grifols, and Teijin Pharma Limited.
Regional Analysis
The main geographies covered in MRFR's report include the Americas, Europe, Asia Pacific, and the Middle East & Africa. The global chronic inflammatory demyelinating polyneuropathy market has witnessed the highest presence in the Americas market. Possessing a share of 52% of the global market, the Americas have a leadership position in the market due to the presence of a significant pool of patients suffering from CIDP. Moreover, the strong presence of several leading players in the market is expected to reveal opportunities for growth. The chronic inflammatory demyelinating polyneuropathy disorder is highly difficult to diagnose as its symptoms can often be mistaken for other diseases or disorders. The Americas developed countries have a highly advanced healthcare system which makes the diagnosis of chronic inflammatory demyelinating polyneuropathy easier, thus supporting the regions market position.
Meanwhile, the Asia Pacific is being projected as the fastest growing regional chronic inflammatory demyelinating polyneuropathy market at a CAGR of 7.03% during the review period. The region has an increased availability of funds for research and development activities due to a growing focus on healthcare and healthcare reform. Moreover, the presence of significant expertise in the region is likely to encourage market growth in the coming years.
Notably, the Middle East and Africa market is also expected to grow at a significant pace due to the presence of emerging economies where the healthcare sector is developing swiftly. Middle Eastern countries, in particular, are anticipated to drive market growth.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Chronic Inflammatory Demyelinating Polyneuropathy Market#Chronic Inflammatory Demyelinating Polyneuropathy#Chronic Inflammatory Demyelinating Polyneuropathy Market Trends#Chronic Inflammatory Demyelinating Polyneuropathy Market news
0 notes
Text
Varicose Veins Treatment Market Sales Revenue, Growth Factors, Future Trends 2027
The global varicose veins treatment market is anticipated to hold a market value of USD 415.9 million and is expected to grow at a CAGR of 7.4% during the forecast period. Varicose veins are knotted, enlarged veins. They can occur in any part of the body, but mostly affect the legs and feet. This happens because standing and walking escalates the pressure in the veins of the lower body.
The increasing demand for less invasive treatment options, rising prevalence of varicose veins, rising investments by major market players and increasing awareness about varicose veins is expected to drive the market growth over the forecast period. For instance, in May 2016 Mr. Luis Navarro opened the Vein Treatment Center in New York for creating awareness amongst the community regarding treatment of varicose veins. However, high cost of treatment, lack of skilled vascular surgeons and extensively competitive market can restrain the market growth over the assessment period.
Regional Analysis:
Geographically, the Americas is expected to dominate the global market owing to a huge patient population suffering from varicose veins and rising geriatric population. According to a data published by the World Bank, 15.41% people in the US were 65 years and older in 2017. Europe is expected to hold the second largest position in the global market owing to the preference for minimally invasive treatment procedures. Asia-Pacific is expected to be the fastest growing market owing to the increasing healthcare expenditure and growing patient population. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global market.
Segmentation:
The global varicose veins treatment market has been segmented into type, product and end user.
The market, on the basis of type, has been segmented into endovenous ablation, sclerotherapy, surgical ligation, spider vein treatment ,lase ablations and stripping. Sclerotherapy is expected to hold the largest market share of the global varicose veins treatment market by type, owing to its simple follow up treatments, no need of anesthesia, no scarring and favorable reimbursement policies. Endovenous ablation is expected to be the fastest growing segment owing to its high preference over the conventional procedures like stripping and surgical ligation.
The global market, on the basis of product, has been segmented into ablation devices, venous closure products and surgical products.
The global varicose veins treatment market, by end user, has been segmented into hospitals, specialized clinics, ambulatory surgical centers and others.
Key Players:
Some of the prominent players in the global varicose veins treatment market are Medtronic, AngioDynamics, biolitec AG, Syneron Medical Ltd., Lumenis, Energist Ltd., Eufoton s.r.l., Teleflex Incorporated, Quanta System, Dornier MedTech, Scranton Gillette Communications, Sciton, Inc, Fotona d.o.o., BTG International Ltd., Merz North America, Inc.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Varicose Veins Treatment Market#Varicose Veins Treatment#Varicose Veins Treatment Market Trends#Varicose Veins Treatment Market news#Varicose Veins Treatment Market Analysis
0 notes
Text
Stereotactic Surgery Devices Market Competitive landscape, future, growth till 2027
The global stereotactic surgery devices market held a market value of USD 16.59 billion in the year 2017 and is expected to grow at a CAGR of 5.2% during the forecast period. Stereotactic surgery is a minimally invasive form of surgical intervention that uses a 3D coordinate system to locate small targets inside the body and perform actions such as ablation and biopsy. The rising preference for minimally invasive surgeries, increasing adoption of stereo static surgery devices, and growing prevalence of brain-related diseases such as Parkinson’s disease, brain tumor, and others is anticipated to drive the growth of the market over the assessment period. According to the National Tumor Society, an estimated 700,000 people in the US were living with a primary brain tumor in 2017 and about 78,980 people are expected to be diagnosed for primary brain tumor in 2018. Moreover, according to reports published by Elekta AB company, an estimated 70,000 patients undergo gamma knife surgery each year.
On the other hand, the high installation cost and low treatment charges delays the recovery of the invested amount which thus limits the adoption of the technology. This factor is expected to hamper the growth of the market over the forecast period. market report offers comprehensive study of the stereotaxic instruments ,Overview, Regional Overview, Segments.
Regional Analysis:
Geographically, the Americas is expected to dominate the global market owing to the rising prevalence of neurological diseases, presence of developed healthcare infrastructure, and high disposable income. Europe is anticipated to hold the second largest position in the global stereotactic surgery devices market. The market growth in this region is mainly due to the increasing occurrences of brain diseases and presence of developed healthcare sector. The Asia-Pacific region is expected to be fastest growing region owing to the growing prevalence of brain-related diseases and continuously growing healthcare sector. The Middle East & Africa has the least share of the market owing to the limited presence of developed healthcare infrastructure in the African region.
Segmentation:
The global stereotactic surgery devices market has been segmented into product type and application.
The global market, on the basis of product type, has been segmented into gamma knife, Linear accelerators (LINAC), proton beam therapy, and cyberknife. By product type, linear accelerators (LINAC) segment is expected to hold largest market share owing to the growing adoption rate and installations. Additionally, cyberknife is expected to be the fastest growing segment over the assessment period owing to its growing popularity in the developing economies.
On the basis of application, the market has been segmented into brain tumor, arteriovenous malformations, Parkinson’s disease, epilepsy, and others.
Key Players:
Some of the prominent players in the global stereotactic surgery devices market are Huiheng Medical, Inc., Mitsubishi Heavy Industries, Ltd., GE Healthcare, Elekta AB, Koninklijke Philips N.V., Varian Medical Systems, Hitachi Medical Systems, Accuray, Inc., Ferring B. V., and Shinva Medical Instrument Co., Ltd.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Stereotactic Surgery Devices Market#Stereotactic Surgery Devices#Stereotactic Surgery Devices Market Trends#Stereotactic Surgery Devices Market News
0 notes
Text
Nutraceutical Excipients Market Research Report 2027 Observational Studies with Key Vendors
The global nutraceutical excipients market valuation of USD 4800 Mn by during the forecast period. Excipients are inactive components added to nutraceuticals during its production to help stabilize the ingredients. Nutraceutical excipients perceive augmenting demand, which in turn, substantiates its market size globally.
Improving economy is undoubtedly one of the key factors propelling the market growth, increasing the quality of life and access to the healthcare. Additionally, factors such as increasing awareness among consumers towards the advantages of Nutraceuticals, expand the growth of nutraceutical excipients market.
On the other hand, some excipients, can initiate or participate in chemical and physical interactions, compromising the efficacy of a nutraceutical. Hence, the regulatory bodies standardize manufacturing and distribution processes of nutraceuticals. They scrutinize the type, quality, and the amount of ingredients added in a nutraceutical, and the labeling criteria for various ingredients that are to be mentioned on product labels.
Nutraceuticals supplements assist in the treatment and prevention of diseases. Medical practitioners advise nutraceuticals so as to provide medical benefits during the treatments for chronic diseases and disorders such as COPD, asthma, cancer, certain heart problems, and diabetes. Increasing prevalence of chronic diseases leads to increase sales of Nutraceuticals, further driving its market growth of Excipients.
These stringent regulations present a number of challenges to the manufacturers limiting the production of nutraceuticals and hence slowing down the consumption and the market growth of excipients used in nutraceuticals.
Global NutrSegmental Analysis:-
On the basis of types, the market is segmented into artificial and natural/organic. In 2017, The artificial segment accounted for the largest market share. This segment is projected to expand at 7% CAGR during the forecast period. However, the natural/organic segment is projected to exhibit a relatively higher CAGR during the review period.
On the basis of functions, the market is segmented into fillers, diluents & bulking agents, binders, disintegrants, sweeteners, coating agents, lubricants, and colors & flavors. Out of these, the fillers, diluents & bulking segment accounted for the largest market share in 2017. On the basis of forms, the market is segmented into dry and liquid. In 2017, the dry segment accounted for 55% of the market share and stood at over USD 1700 Mn. The segment is forecasted to witness a healthy CAGR during the assessment period.
On the basis of Applications, the market is segmented into Probiotics & Prebiotics, Proteins & Amino Acids, Omega-3 Fatty Acids, and Vitamins & Minerals. The probiotics & prebiotics segment, in 2017, accounted for 47.5% of the market share, valuing at USD 1476.17 Mn. The segment is forecasted to register a strong growth during the estimated period. The vitamins & minerals segment is likely to post a CAGR of 7.92% during the review period.
Regional Analysis:-
Globally, the North America market dominates the nutraceutical excipients market. Increasing prevalence of respiratory diseases and chronic diseases drives the market growth in the region. The sedentary lifestyle is the primary factor fuelling the incidences of chronic diseases.
Also, other factors like the rising geriatric population, increasing healthcare expenditure, coupled with the growing awareness among people towards the benefits of healthy diet, are increasing sales of nutraceutical and hence the market growth of nutraceutical excipients in the region.
The Europe market accounts for the second-largest market for the Nutraceutical excipients owing to the presence of well-established players and growing healthcare expenditures in the region. Certainly, the resurging economy is the main driving force increasing the market value in the region.
The Asia Pacific nutraceutical excipients market emerging as the fastest growing market accounts for a substantial market share on the global platform. Factors such as the proliferation of healthcare sector in populous countries such as India and China substantiate the market growth in the region.
Increasing geriatric populace, rising cases of patients suffering from the chronic diseases, growing awareness about the healthcare, and increasing demand for sports nutrition & health supplements influence the market growth positively.
Competitive Analysis:-
Key players operating in the global Nutraceuticals Excipients market include Cargill Corporation, Ingredion, Associated British Foods plc., Kerry, Roquette Freres SA, JRS PHARMA, Innophos, Inc., DowDupont, Sensient Technology Corporation, and Hilmar Ingredients among others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Nutraceutical Excipients Market#Nutraceutical Excipients#Nutraceutical Excipients Market Trends#Nutraceutical Excipients Market News#Nutraceutical Excipients Market Research
0 notes
Text
Injection Pen Market Astonishing Growth with Top Influencing Key players
Acknowledging the increasing market size of the market, Market Research Future (MRFR) in its recently published study report asserts that the global injection pen market will garner exponential accruals registering approximately 6.5% CAGR throughout the review period.
Injection Pens are designed for easy and convenient administration of intravenous drug delivery. These devices are commonly used during treatments of chronic diseases like cancer and diabetes. With the increasing occurrences of chronic diseases such as diabetes, cancer, and osteoporosis the global injection pen market is proliferating over the past few years.
Furthermore, factors such as the increasing uses of biologics are helping the market to increase colossally. Moreover, the growing preference of pen injector over the traditional vial and syringe method majorly led by the increasing cases of needlestick injuries are escalating the market on the global platform.
Additional factors positively impacting the growth of the market are the increasing number of technological advancements, improving patients’ experience, beneficial reimbursement policies, and the rising awareness towards healthcare.
On the other hand, reimbursement issues in developing countries and the introduction of alternative drug delivery injectables are some of the key factors impeding the growth of the injection pen market.
Global Injection Pen Market – Segmentations
For ease of understanding, the MRFR analysis has been segmented into six key dynamics: -
By Type : Disposable and Reusable Injection Pens among others.
By Product : Insulin Pens and Needles Pens among others.
By Therapy : Diabetes, Fertility, Growth Hormone Therapy, Osteoporosis, Cardiovascular Diseases, Multiple Sclerosis, Rheumatoid Arthritis, Obesity, Cancer, and Crohn’s Disease among others.
By Distribution Channel : Hospital Pharmacies, Retail Pharmacies, Online Medical Stores, and Diabetes Clinics among others.
By End-user : Home Care and Hospitals & Clinics among others.
By Regions : North America, Europe, Asia Pacific, and the Rest-of-the-World.
Global Injection Pen Market – Geographical Analysis
The North American region, heading with the increasing prevalence of diabetes and cancer accounts for the leading market in the global injection pen market. Factors such as the development in medical technology, a growing number of approvals, and subsequent launches of new products, the presence of geriatric population, and a vast patient pool suffering from chronic diseases are supporting the growth of the market.
North America is a well-developed region with the highest GDP, worldwide, which helps the region to have the edge over other regions in terms of every aspect including healthcare and technology.
Certainly, the high economic growth is a key force driving the market growth in the region, allowing access to the quality of life for the people. The US, backed by the high per capita healthcare expenditures, contributes to the growth of the regional market, significantly. Owing to the augmenting demand for the injection pen, the region is projected to create a larger revenue pocket in the global market during the forecast period.
The injection pen market in the European region stands the second-largest position, globally. The presence of a well-established healthcare sector alongside the increasing prevalence of chronic diseases predominantly drives the growth of the regional market. The resurging economy is playing an important role in market development, allowing the proliferation of the healthcare sector in the region.
Furthermore, favorable government policies is a key driving force contributing to the market growth in the region. Germany, due to its flourishing medical devices markets adds on to the growth of the regional market, hugely. Whereas, the U.K. and France with the increasing investment drive the injection pen market in the region.
The Asia Pacific injection pen market is rapidly emerging as a profitable market, globally. Some of the factors defining the landscape of the market include a huge patient population and the rapidly developing countries such as China, South Korea, Japan, and India. Furthermore, factors such as the rising demand for quality devices in healthcare and rapidly expanding healthcare technology are expected to lead the APAC injection pen market.
Global Injection Pen Market – Competitive Landscape
Fiercely competitive, the global injection pen market appears to be fragmented with the presence of many well-established players having a global reach. Brand reinforcement, M&A, and innovation remain the popular trends for these key players.
Major Players:
Key players leading the global injection pen market include Eli Lilly (U.S.), Novo Nordisk (Denmark), Sanofi (France), Ypsomed (Switzerland), Merck (U.S.), AstraZeneca (U.K.), Becton Dickinson and Company (U.S.), F. Hoffman-La Roche (Switzerland), Owen Mumford (U.K.), Haselmeier (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Biocon Ltd (India), and Jiangsu Delfu medical device Co. Ltd (China) among others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
0 notes
Text
Yeast Infection Treatment Market Demands, Insights, Research and Forecast 2020-2027
The global yeast infection market is well-established and is growing pervasively. Increasing prevalence of the infection fuelled by the predominant risk factors such as widespread use of antibiotics and possibly even global warming contribute to the growth of the market. Moreover, factors such as well spread awareness towards this kind of infection and the availability of novel medications and treatment procedures are proving impetus to the market growth.
Acknowledging the kind of traction, the market perceives currently, Market Research Future (MRFR) in its recently published study report anticipates that the global Yeast Infection Treatment Market will garner exponential accruals by 2023, registering approximately 5.2 % CAGR during the forecast period (2017-2023).
The genital area in women is prone to yeast infections. Yeast infections are a result of fungus growth that reaches a finale of inflammation, blisters or painful discharge. Certain health conditions resulting in recurrent infections in women are pregnancy, disability, premenopausal, or postmenopausal, immunocompromised patients with diabetes, or women who are taking estrogens replacements are at an increased risk for recurrent vaginal yeast infections.
Improving economic conditions worldwide that enables access to the quality and improved healthcare fuel the market growth. Additional factors propelling the market growth include the changing or unhealthy lifestyle & pollution owing to the growing urbanization & industrialization. Technological advancements in the medical science backed by the substantial investments made in the R&D activities foster the market growth of yeast infection treatments excellently, bringing about innovative treatments and medicines.
On the other hand, incidents of unmet clinical needs, drug resistance, complications occurring during treatments and side effects of the treatment are some of the factors expected to impede the market growth during the forecast period. However, factors such as rising demand for antifungal drugs and government support for research & development are expected to support the market growth.
Global Yeast Infection Market - Segments
Global yeast infection market is segmented into five Key dynamics for an easy grasp and enhanced understanding.
By Pathogens : Candida Albicans, Candida Glabrata, and Candida Rugosa, among others.
By Types : Skin Yeast Infection, Vaginal Yeast Infection, and Throat Yeast Infection, among others.
By Treatments : Drug Treatments (cream, ointment, tablet, and suppository.), and Surgery among others.
By End-Users : Hospital, Clinics, and Ambulatory Centers among others.
By Regions : Europe, North America, APAC and Rest of the World.
Global Yeast Infection Market - Regional analysis
The North America region accounts for the largest market share in the global yeast infection market followed by the Europe & Asia Pacific regions, respectively. The yeast infection market in North America is growing due to the significant contribution from the significantly increasing market for the U.S. due to the increasing number of patients suffering from immune diseases and presence of huge geriatric population.
Furthermore, the significant market share of the US market attributes to the growing prevalence of yeast infection coupled with the high expenditure on the health care. On the flip side, the regulatory changes in the US such as the implementation of the Affordable Care Act are expected to take a toll on the US yeast infection market.
On the other hand, the yeast infection market in Europe accounting for the world’s second-largest market is growing due to the higher per capita income and strong healthcare penetration in the region. Furthermore, factors such as the availability of advanced treatment facilities, skilled medical professionals, yeast infection medication and government support for research & development drive the growth of the regional market in the large scale.
The Asia Pacific region is rapidly emerging as a lucrative market for the yeast infection. Countries such as China and India backed by the huge population and the low-cost medications and procedures available to treat the yeast infection foster the market growth in the region. Moreover, the rapidly growing healthcare sector coupled with the large unmet needs over the forecast period will provide impetus to the market growth.
Global Yeast Infection Market - Competitive Analysis
The global yeast infection market is a fragmented market with a large number of players. Increasing cases of drug resistance have opened doors for new drug development and opportunities for a new market leader. The increase of spurious and counterfeit medicines have reduced the total market revenues and at the same time displaced standard drugs off the market.
Key Players:
Some of the eminent leaders fostering the global yeast infection market include Synmedic Laboratories (India), Scynexis (US), Merck & Co., Inc. (US), Bayer AG (Germany), Astellas (Japan), Mentis Pharma Ltd. (India), Novartis AG (Switzerland), Abbott (US), Pfizer Inc. (US), ALLERGAN (Ireland), Sanofi (France), and AstraZeneca (UK).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
#Yeast Infection Treatment Market#Yeast Infection Treatment#Yeast Infection Treatment Market Trends#Yeast Infection Treatment Market News
0 notes